S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
NASDAQ:RTRX

Travere Therapeutics - RTRX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$27.03
$28.65
50-Day Range
$24.25
$28.18
52-Week Range
$8.98
$24.96
Volume
454,289 shs
Average Volume
412,277 shs
Market Capitalization
$1.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RTRX stock logo

About Travere Therapeutics (NASDAQ:RTRX) Stock

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RTRX Stock News Headlines

Analyst Ratings for Travere Therapeutics
Travere Therapeutics Inc
Retrophin rebrands itself as Travere Therapeutics
Retrophin Completes Acquisition of Orphan Technologies
Retrophin EPS beats by $0.07, beats on revenue
Retrophin: 3Q Earnings Snapshot - Yahoo Finance
Retrophin Reports Third Quarter 2020 Financial Results
Retrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates
See More Headlines

Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RTRX Company Calendar

Last Earnings
11/05/2020
Today
8/16/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RTRX
Fax
N/A
Employees
221
Year Founded
N/A

Profitability

Net Income
$-146,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$175.34 million
Book Value
$5.15 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.46 billion
Optionable
Optionable
Beta
0.67

Key Executives

  • Eric Dube
    President, Chief Executive Officer & Director
  • Laura M. Clague
    Chief Financial & Accounting Officer
  • Bill Rote
    Senior VP, Head-Research & Development
  • Noah L. Rosenberg
    Chief Medical Officer
  • Elizabeth E. Reed
    Secretary, Senior Vice President & General Counsel













RTRX Stock - Frequently Asked Questions

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:RTRX) issued its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%.

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Travere Therapeutics investors own include CVS Health (CVS), Gilead Sciences (GILD), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Novavax (NVAX), Sangamo Therapeutics (SGMO), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK) and Exelixis (EXEL).

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "RTRX."

What is Travere Therapeutics' stock price today?

One share of RTRX stock can currently be purchased for approximately $28.59.

How much money does Travere Therapeutics make?

Travere Therapeutics (NASDAQ:RTRX) has a market capitalization of $1.46 billion and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Travere Therapeutics have?

The company employs 221 workers across the globe.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The biopharmaceutical company can be reached via phone at (888) 969-7879 or via email at ir@retrophin.com.

This page (NASDAQ:RTRX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.